Thank everyone, thank on this call for you, and joining our on you recent Mike. update Good financial our afternoon, and you results. us discuss quarterly to business
been report accomplishments Although weeks, exciting to we've since very last milestones and its six been active on. our update with upcoming only many
facing the of safe pandemic. -- you can update by me ones start we're challenges are last love all a our ongoing words with let as the up work. first result able healthy, pray their and hope the safe. and about as important hoping yourself PAVmed As and the and COVID-XX we thing with few start of family all holding that are Thankfully continue keeping to your best members all of you I'll
challenges disruptions and corporate structure to strategic anticipated to serve these continue and short-term our plan. Our no really well we far so confront with as long-term as minimal culture
discuss how that first area affected to has are are Before respond been has providing or each and continuing not we those pandemic let's affected. our the product our on you of updates how portfolio, to with business by
previous with in and more we a the as convertible On financing the will financing. Dennis administrative financial completed investor convertible note same explain side note recently detail our shortly, as
the $XXX,XXX form proceeds Protection from in the Program, loans. PPP a of received also approximately of Paycheck We the forgivable
as the sheet foreseeable full strategic balance through future plan and support for strong is will upcoming advance we milestones. our Our
meaningful financing sales remain begin activities. in operations or revenue commercial We to we our diluted continue non generate confident ability until M&A finance these through to to through
XX. our full-time cash under our lean We at board-approved on at remain count We focused to and management. continue be budget or remains laser head
experienced development product, have manufacturing essential partners disruptions behalf. remained of and the fully operational on fortunately, a we've their our product over as meaningful all and services dozen, and development they our no side, number manufacturing in On activities
cases one in intact This but as release backorder a the dramatic ventilator that's only in CarpX pressure on production. There's ramp-up chain the a first exception. spike the supply circuit the will first U.S. -- lot devices few demand board the with also sensor Our COVID-XX a weeks. result of only by related has delay in commercial of to CarpX we remained clinical on but of due
On front, of FDA. consultants our engagement impacted the regulatory not work regulatory our with including regulatory the any the and by pandemic activities has ongoing
fact, CarpX most CarpX in weeks around FDA after less six than clearing know you the In rapidly our turned of as XXX(k) application submission.
disruptions we Two result of commercial the are related activities. a on know commercial areas. managed our the The stream system successfully has a where research resources clinical have which you faced COVID-XX hotspot side, healthcare the hospitals as massive and all overwhelmed and areas pandemic,
procedures to standstill. came diagnostic Non-emergency care and a including surgical
will parts being whether outbreaks to engine country of parts the many and can't emergency is in future performed again. the starting back coming again of procedures lead the in predict we online disruption, elective not most Although are definitely or country. Non up renewed procedures are
Although safe pent-up on these facilities. pace patients to safety when impact to and new there it's procedural return is believe medical of the lot depend the of how demand reboot efficiency for services, a measures will
commercial that more absolutely the amazing, to but EsoGuard the later, in job amazing -- team activities pandemic. done later commercial detail discuss our will an constraints of more to adapting I proud has I'm in say
accounts product. We independent continue sales calls, shipping them train them, to participate in us reps, recruit with opening sales have virtual and
start We couple clinical activity expect coming elective up the as months picking ramps up. weeks -- in and rolling in the to procedural
I clinical summarize sponsored research, both two a and good fact clinical full a advisors non-COVID-related told which me in all will has One came nationwide, endoscopy, is has the schedule nearly closest PAVmed corporate fact of he that today halt trials worldwide side, research which months grinding to multiple in our clinical In gastroenterology a academic and of which later. sign. ago, impacted Lucid
continue up starting centers as approvals, trials uninterrupted week. as did to engine enroll the starting clinical recruit executing well and trial with our on This and agreements. again over negotiating IRB patients to past in is also Work rev
So, since deeper have products, I'll into receive to marketing Invasive some Carpal from accomplishments last to in that lead those FDA clearance Device. our U.S. occurred diving the CarpX the were individual ones to for Tunnel try with thrilled update. start before recent we limit Minimally I April, mentioned XXX(k) the
to CarpX We the IVD three started patients clinical and a in international at U.S. sites XX This our multi-center sales month, manager today the EsoCheck comparing EsoGuard one Europe. recruited we this first enrolled in trials successfully who national has week. including endoscopy and
in payment our payment We an and for I'll describe completed diagnostics largest the Device, We animal successfully GBA submitted an of dossier EsoGuard. securing its which final detail. molecular Dx, EsoGuard study EsoCure, Ablation in to Palmetto Medicare Mol acute important step Esophageal program, contractor,
dates us for and our step PAVmed opinion firm of is a pursue to in quality received Lucid audit Stage the their our CE body, required by critical Both products. system Mark X for your for notified EU which clearance
a diagnostic non-invasive completed wide NDIR of glucose a Our laser subsidiary, based blood Diagnostics initial testing concentrations. of response range linear across demonstrating glucose bench-top device our Solys
subsidiaries. property includes either XXX advance portfolio licensed intellectual and always pending patents and over expand issued and has now or Finally, to our continues assigned their extensive to and PAVmed
the months, coming are and milestones here the activities highlights. over key So some of few what are upcoming
Medical a and hand of CarpX launch commercially recruit will Board We world-class Advisory surgeons.
continue We expanding of representatives. sales EsoGuard commercial our network activities to an will accelerate independent through
procedures. As professional to and medical in-person facilities and engagements -- education open from we'll ultimately we'll transition transfer up virtual sales
and the coverage submit CPT code will Palmetto hopefully GBA a we Now secure payment EsoGuard the which and possible. dossier sister Medicare as as coverage payment for and other to contractors dossier soon decisions to is EsoGuard's
COVID-XX. and trials additional will and clinical and we'll As our in been involving currently PortIO, ESOGUARD-BE-X on elective which procedures trials also four X enrollments because restart, hold have EsoCheck we accelerate launch of
M&A will involving continue partnership very discussions -- which consummate disappear, now to we We in months. active coming EsoCheck and EsoGuard, we are the hope NextFlo, and
hope which commercial down of blood and to their and to accuracy path. critical animal allow diagnostic us proceed achieve human in the development Finally, device, initiate will milestone testing Solys glucose we
I'd Innovations. specific and Invasive Health, our like GI some now Therapy Minimally to more Emerging Infusion across which updates are four divisions, provide Interventions,
Health. Starting with the GI
Health of products, EsoGuard, to of EsoCheck diagnose division esophagus. conditions complementary building and are which the designed and family treat Our EsoCure, GI a is
disease the spectrum include These GERD, also reflux lethal which reflux esophageal as rise or conditions, known and chronic of heartburn and gastroesophageal cancer. from polluting to Barrett's Esophagus, highly lead can
mediated related is but multiple condition that's course during currently The invasive Esophagitis, other and bowel disease targeting to area allergy underappreciated with which these we of treatment. similar very are a products Eosinophilic the requires inflammatory endoscopy common
University. team and our I'm which short EsoCheck I been of the time. founding of partners partners am and the Case subsidiary can't Western have at what accomplish Reserve marked really the our anniversary how of week license say Lucid our from period in of technologies EsoGuard proud Last two-year really Diagnostics, able to a our
EsoGuard progress rapid XXXX. now in technology an and hope available and groundbreaking Innovations added making our We EsoCheck complementary we diagnostic commercialize EsoCure is from are a and to tools. division this this commercially Emerging
programs discussions on ask biomarker stay the tests space other we're you addition, In other and to including and pursuing that active tuned partnership front. research for in products
Precancerous new test. lethal designed and EsoCheck Just highly and you changes early office based dysplasia cancer esophageal detection and and to groundbreaking to -- are then a for highly called to are those so facilitate products. are do PAVmed non-invasive Esophagus. They Barrett's who of EsoGuard using esophageal are Lucid, that to of
than third recommended XX before it fewer cancer and Although screening upper treat XX% screening progresses invasive high-risk endoscopy. over patients using the actually undergo million Barrett's in detect is to
have patients of five this aware through the ultimately cancer majority cancer have if of vast consequence years. not and are that patients could Barrett's tragic been will progression their with die had diagnosed Barrett's of treatment The monitoring they prevented esophageal the that underlying cancer and just earlier. XX% diagnosed these of within is the Over careful esophageal that been of
of acknowledged products granted in potential to prevention device this these designation ea which EsoGuard report one been and significant National highlighted impact Institute year's early FDA of EsoCheck has in them as advances by the breakthrough and The XXXX year. life-saving the cancer Congress the Cancer which
EsoCheck as a the was best among also device the recognized year. Award Winner, Edison XXXX medical products of new
those on work. us brief just these overview are a learning you about for of how again Just devices
from as the sampling cells lower of perform is FDA-cleared which of lining the and collection office-based noninvasive esophagus procedure. EsoCheck the part a protected cell five-minute can device, a targeted
is under anesthesia to serve accurate which in along which dedicated EsoGuard or cancer center. patients detect alternative endoscopy, invasive to Barrett's the DNA spectrum. an upper hospital a changes highly endoscopy is a Its occur performed as esophageal epigenetic under in which test
its with EsoGuard U.S. commercially LDT. or test samples developed available performed laboratory collected is EsoCheck a on and as
modest very penetration market to assessments U.S. screen. already be domestic commission BE estimated billion addressable third based have patient Our of products for the these for several on recommended opportunities dollars market
formally EsoGuard has The We are rapidly hybrid closely working using sales with professional commercial five ago. education, with sales model grown a since team EsoGuard commercializing launched and internal management, reps. marketing months independent
Our independent of highly managers network our with most Chief Commercial and Eastern the Communication of and Officer, Director reps a are and partnered country. Western growing sales rapidly of Marketing experienced sales covering
all with averaging relationships long-standing These with their most professionals in are with senior the a leading field, least dozen territory. gastroenterologists years in at companies and
are independent are under to every sales and We currently ones now new up adding XX week. contract rep
Over with their as restarting of dramatically virtual in number increased calls restrictions the COVID-XX the last has relax week sales procedures. two elective anticipation of physicians
now has been logistics well. accounts been to new community contact the account from provider to extremely product several accepting week has back They and a and this hundred with our made response have We're new shipping as gastroenterology positive. application sites probably
on we're one Next feel accounts for training strongly running and in and the one on-site virtual allowed do our will we'll to the mark successful We of in week until will Midwest. we be to until regulation get get site a short continue the as term that lift. way support this up first --
anticipation We're reopening. support also in this clinical specialists recruiting of
the sales We aggressive EsoCheck of and generate condition and brand continue underline and social to awareness marketing our patients product. physicians recognition and strengthen campaign EsoGuard media, the targeting journals and support professional,
to over highlighting advantages been the months. been in alternative begin excellent In the feedback these growing, with has will addition, the positive. and has very we product and Engagement activities of coming our start the clear
successfully designation. code also the us and front. coverage to the proceed to following payment through progress CPT solid make with allowing advanced year EsoGuard a We CMS continue the and gap-filled on on so-called discussion process received last reimbursement
We have diagnostic the Dx. and largest successfully contractor engaged its two with parallel Palmetto efforts Medicare Mol These molecular group paths; GBA, followed coverage. and payment
We're final on the and will We fee both coming payment have optimistic supporting favorable in submitted decisions months. a the submit final that we our coverage receive request coverage. payment dossier dossier and will
the an disposable, thermal ablate of we balloon device. the technology uses ago, is in patented that's our channel esophageal a to tissue. ablation days designed development of exciting EsoCure EsoCure, our catheter milestone and ablation endoscope standard pelvis to working Two esophageal reached single-use advance the to
dysplastic expensive Once cleared for the to progress capital clinicians equipment. to and without Barrett's it the commercialized, EsoCure or do can dysplasia treat complex and would allow so need cancer. before And
The radio Medtronic device, tools, are to pass an endoscopes high-margin multiple Barrett's is the current and market large the requires disposal through ablation leader in channel. this of and too disposable equipment which expensive large which ablation tool, piece capital most of frequency working
the than of radio centigrade which bench XX seconds, within first We a this device. achieved prototype degree frequency testing and XX significantly working completed rapidly over higher consistently temperatures Medtronic more ablation
animal as prototype. testing exactly designed. performed the completed device as This of were week initial the results successfully stunning The we
device Although charring existing and very is circumferential what intervals expensive clear over pending, radiofrequency without ablation performed short platform. final compared pathologic required the time consistently to XX:XX analysis with
expect and in have hope submission We to year. XXX(k) to XXXX early commercialized that complete of later it EsoCure development by FDA
clinical and COVID are front, gear slowdown. EsoCheck starting On up activities trial the following to related EsoGuard
trials; multicenter and submission to and and EsoGuard the U.S. in-vitro over clinical are designed Our FDA of Europe. PMA includes support registration IVD and in has future or two diagnostic X ESOGUARD-BE-X international sites XX EsoCheck a for
staggered state to practice BE-X that back society with patient academic on of few and one guidance of the of three weeks based patient over the type of a institutions patients has acceptance with CDC, private factors, a study, in scheduled versus today screening professional reopening be three several larger including The enroll accordance month. the on including We the site this anticipate research we're additional campus.
have is all on a timeline a drive on forecast key the new multiple played which executed over our currently The original which allowing We've us intact. building enrollment also will timeline. keep role team contingencies to
all nearly take institutions enroll more will will large the be to be We their in will anticipate in enrolling that for up infrastructure order gear -- expected research. The to of our coming months. time sites as reconfigure
EsoCheck clinical but enrolling soon. are also additional hold, begin should trials Two on
work at Fred Cancer surveillance prior the EsoCheck greatly could Hutchinson in non-dysplastic Barrett's of to facilitate development first designed the dysplatic The they this can at the progression study role but looking cancer. detect the patient, and of Center from to Seattle is to treated biomarkers of Barrett's, so be
a the are exclusive we we the with license at if Pennsylvania previously clinical patients will the and they look And the to option trial. announced eosinophilic The biomarkers treatment secure study role these study, EsoCheck monitoring prove effective in different esophagitis. University of
discussions two have GI we product. active Health Finally, partnerships involving
once we'll diagnostic interest restrictions perform that strong to EsoGuard U.S. and market up. be revisiting from have that established We outside company region and in COVID-related the travel ease
to a opportunity look biomarkers that forward consummating We academic also from we as to an major the esophagitis near LDT, future. accurate been center the offered eosinophilic medical for commercialization highly and license in
month, CarpX that excited our moving Minimally XXX(k) invasive than FDA clearance we treat to our very syndrome. Carpal for Invasive we've encompasses minimally to to which after six on less are tunnel single-use designed announce CarpX submission device received last weeks division Interventions, disposable So marketing
it activated while Carpal ligament, under balloon nerve is pushing that a bipolar widely second. very burden away. electrodes inserted on matter ligament this the exacts tunnel large is and out clinical tensioning precisely inside cut syndrome condition in The tendons and catheter of a society. scar's economic a the from the When prevalent radiofrequency
dramatically time reducing tunnel will cleared the Carpal many compared technique and patient We based market carpal traditional in and to currently tunnel the utilize first facilitate to I CarpX, surgery suffer XXX,XXX to of tunnel billion CarpX wire invasive only roles. revolutionize now estimated now estimated catheter treatment carpal by believe an XXX(k) dollars U.S. common open recovery minimally syndrome surgery opportunity who and is So CarpX more balloon device on invasive silence. and undergoing is
who As and FDA, better met a study follow-up the assessment safety performed surgery. open traditional outcome completed performed results safety the the -- expected effectiveness similar well endpoints, in in were to human submitted Zealand we and human additional previously prespecified study clinical in from or to CarpX all patients prespecified announced, New very than
curve as procedure Importantly, the in learning that spell time short be or traditional procedural open the CarpX after performed indicating time less can same surgery.
We Manager, have recruited he's CarpX a Sales National We're starting Dan excited, this week. Dargis.
pen advisers professional sales surgeons world-class network Dan calling independent and vast of orthopedic of who board to his surgeons ties beginning the and product our of both sales helping has also strong us education and network lead he recruit his the decades iterative U.S. initial is commercial a independent and and experience these. activities rep on Dan advisory to will cases, reps. is on the procedure in development outreach hand perform of space
a Our pressure the backorder, the sensor mentioned, commercial as we look I and launch in launch, delayed weeks coming of months. to few that's has that but forward been on weeks because
infusion therapy some division, Next, from highlights NextFlo PortIO. our which includes brief and
platform NextFlo is deliver infusion. accurate to technology a highly
a We for nutrition. intravenous disposable infusions, military patient range infusion and are broad home pumps of trauma prepackaged outpatient and use, drug applications in application pursuing infusion,
the further which The mix. States. IV is application, million We is electronic height pump of need IV the for in infusions the it infusion the set, of most, delivers not NextFlo day believe but most highly gravity driven of which each intravenous and United the expensive delivered the X independent infusion or accurate for infusion will all, along estimated complex eliminates
set, IV and the control, We're testing year. FDA of development before submission making really excellent progress XXX(k) and end NextFlo with we're design, targeting the infusions the
discussions home application. drug -- as infusion as this the the very space subject disposable well prepackaged in space key the Our infusion for use NextFlo also active a of M&A in particularly pump, remains strategic of with active very
is access implantable PortIO market bone based current PortIO. which to kidney and interosseous opportunity direct must on substances or fluid dialysis. an access $XXX addressing estimated allows to be deliver for veins whose veins poor and to failure the our failure, with medications million On renal device, preserved those with marrow carefully vascular other patients future
We're short-term clinical pathway. center safety now participated meeting we the on study. the the with de sorry, Earlier pre-submission -- the successful initial through year this seeking seeking, indication FDA's are in single are a implant focus we for novo duration FDA protocol an clinical we
Zealand perform the or we're New of into and to investigational application but submitting plan like moving be travel the did U.S. an we'll CarpX, soon. in study have FDA because We this with Exemption restrictions Device an we IDE to
do plan or long-term to in remarkable we still flushes. to We results study documented of any South a completely animal of the replicate maintenance which perform showing six-month patency Columbia, free device study PortIO the America
time We have Columbia sites And touch to again sort begin in principal forces and of and and highlight. things three investigators the projects working Emerging we're locked open me have exciting three Innovations you down if to enrolling but up. in division, training on hope once on the just once our
and curve concentrations. working NDIR The bench-top range These progressing mentioned, Solys for technology glucose response has model. prototype show blood very very research well. plan across development noninvasive and a nice is fairly Diagnostics wide linear monitoring I laser-based of tested glucose has results been As a our a recent been in completed
threshold achieve will be to testing commercial If We to able our development -- coming proceed well expect and be that on and in we human we accuracy goes the complete to target plan. animal weeks. a
year made X that the tubes. past expect and silk bilateral tubes, place from been process tube partner AquaCel activities ear technology and the undergo commercial is scalable but also estimated pediatric of limiting our with are seek the on basis children resorbable made stalled secure who into shortly. care who revolutionize factor ear our has has progressing, has securing the such each a cure partnership million to that capacity to We DisappEAR, progress a molded the a good to recent On over
so space. the including with other earlier the the ventilator ECMO ventilator The in in that important last working we're project team R&D product Our ECMO stage product exciting was week. several about had cardiopulmonary space week, excited this is project Emerging Innovations some very has support also And launched and that. breakthroughs on
there on our to So I'll the financial stop mic for and pass results. review Dennis of a
